Patents by Inventor Sang Gu Yeo

Sang Gu Yeo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant vaccinia virus derived from KVAC103 strain
    Patent number: 9879281
    Abstract: Disclosed herein is a novel recombinant virus vector derived from the attenuated vaccinia virus strain KVAC103. The recombinant virus vector is obtained by inserting an exogenous gene into the KVAC103 and may be used as a safe vaccine delivery vehicle in mammals. Particularly, recombinant viruses obtained by rescuing some of the genes deleted from the parent virus have an enhanced ability to proliferate in cells being cultured, and thus are easily produced. In addition, the recombinant viruses express an increased level of an exogenous antigen, and thus has enhanced immunogenic efficacy. Such recombinant virus vectors may be used in vaccines for preventing diseases, therapeutic vaccines, and molecular biological studies.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: January 30, 2018
    Assignee: KOREA CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Ho Sun Son, Sang Gu Yeo, Sang Won Lee
  • Attenuated vaccinia virus KVAC103 strain
    Patent number: 9879232
    Abstract: The attenuated vaccinia virus strain KVAC103 was obtained by subculturing a vaccinia virus strain 103 times in VERO cells. The attenuated vaccinia virus strain KVAC103 has significantly low toxicity, shows reduced skin lesions, and, at the same time, induces effectively immune responses to poxvirus. Thus, it can be used as a poxvirus vaccine while causing less side effects.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: January 30, 2018
    Assignee: KOREA CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Sang Gu Yeo, Ho Sun Son, June Woo Lee, Seung Bin Cha, Sun Hwa Lee, Kwi Sung Park, Sang Won Lee
  • RECOMBINANT VACCINIA VIRUS DERIVED FROM KVAC103 STRAIN
    Publication number: 20160108371
    Abstract: Disclosed herein is a novel recombinant virus vector derived from the attenuated vaccinia virus strain KVAC103. The recombinant virus vector is obtained by inserting an exogenous gene into the KVAC103 and may be used as a safe vaccine delivery vehicle in mammals. Particularly, recombinant viruses obtained by rescuing some of the genes deleted from the parent virus have an enhanced ability to proliferate in cells being cultured, and thus are easily produced. In addition, the recombinant viruses express an increased level of an exogenous antigen, and thus has enhanced immunogenic efficacy. Such recombinant virus vectors may be used in vaccines for preventing diseases, therapeutic vaccines, and molecular biological studies.
    Type: Application
    Filed: October 15, 2015
    Publication date: April 21, 2016
    Inventors: Ho Sun Son, Sang Gu Yeo, Sang Won Lee
  • ATTENUATED VACCINIA VIRUS KVAC103 STRAIN
    Publication number: 20160106829
    Abstract: Disclosed herein is the attenuated vaccinia virus strain KVAC103 obtained by subculturing a vaccinia virus strain 103 times in VERO cells. The attenuated vaccinia virus strain KVAC103 has significantly low toxicity, shows reduced skin lesions, and, at the same time, induces effectively immune responses to poxvirus. Thus, it can be used as a poxvirus vaccine while causing less side effects.
    Type: Application
    Filed: October 15, 2015
    Publication date: April 21, 2016
    Inventors: Sang Gu Yeo, Ho Sun Son, June Woo Lee, Seung Bin Cha, Sun Hwa Lee, Kwi Sung Park